Addition of AKT inhibitor capivasertib (AZD5363) to sarcatinib can simultaneously inactivate the AKT-S6 axis and Src signaling in HNSCC cells, leading to enhanced treatment outcomes than monotherapy. The gene discussed is SRC; the disease is head and neck squamous cell carcinoma.